SureTrader Advertisement Advertisement Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus Bioscience Holdings Inc. (AMBS)

Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator alexander77, joboggi, zoomboom, JJAAMMAANN, Rosym
Search This Board:
Last Post: 11/29/2015 11:32:30 PM - Followers: 730 - Board type: Free - Posts Today: 0


(AMBS) Amarantus BioScience Holdings, Inc. 

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.

The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a
 diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.  (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. 
For further information, please visit, or connect with the company in FacebookTwitter, LinkedIn & Google+






Amarantus Selected by People's Bank of China for Anhui SME Cross-Border Investment and Trade Cooperation Conference
NOVEMBER 13, 2015
SeeThruEquity Issues Update on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) Highlighting Partnership with U.S. Army and Orphan Drug Application for Eltoprazine
November 5, 2015
Amarantus Announces Issuance of Australian Patent No. 61/057,713 Covering Eltoprazine Treatment of Parkinson’s Disease and Alzheimer’s Disease
Oct. 29, 2015
Amarantus Appoints Curtis Scribner, MD MBA as Sr. Vice President of Regulatory Affairs
OCTOBER 26, 2015   
Amarantus Submits Orphan Drug Designation Application to US FDA for Eltoprazine in the Treatment of Levodopa-Induced Dyskinesia
Oct. 22, 2015

Amarantus to Present at BIO Investor Forum 2015
Oct. 19, 2015
Past President of the American Burn Association Dr. David Ahrenholz Provides Video Interview on Potential of ESS for Treatment of Severe Burns
October 14, 2015
Bio-engineering skin to treat severe burns - Military researchers are putting the final touches on a study of a "skin substitute" grown from a patient's own cells to treat complex burns and soft tissue injuries.
October 11, 2015
Amarantus Reports Preliminary 13-Year Longitudinal Follow-Up Human Patient Data for Engineered Skin Substitute Treatment of Congenital Giant Hairy Nevus
OCTOBER 08, 2015

Amarantus Announces Publication of Study on Targeted Delivery of MANF to Brain Areas Associated With Parkinson's Disease
OCTOBER 06, 2015
Amarantus to Present at the 2015 Aegis Growth Conference
Oct. 05, 2015

Amarantus to Focus Near-Term Development Efforts on Engineered Skin Substitute for Indications in Rare Pediatric Diseases
 OCTOBER 01, 2015
Amarantus Closes $5.5 Million Capital Infusion Through the Issuance of a Combination of Preferred Stock and Secured Debt Convertible
OCTOBER 01, 2015
$AMBS OTC Markets Group to Host Virtual Investor Conference for OTCQX Life Science Companies – October 1
Sept. 28, 2015
A leg up on multiple sclerosis (and Alzheimer’s)
September 2015
Amarantus Receives Orphan Drug Designation From the U.S. Food and Drug Administration for MANF for the Treatment of Retinal Artery Occlusion
SEPTEMBER 14, 2015

More News

Bio-engineering skin to treat severe burns


ESS Patients: Dr. Ahrenholz Interview Part 1
ESS vs the Competition: Dr. Ahrenholz Interview Part 2
The Need for ESS: Dr. Ahrenholz
Interview Part 3
 Gerald E. Commissiong on LymPro 
Published on Jul 24, 2015
 Predicting Alzheimer's before it      starts Published on Apr. 8, 2015
SNNLive - Amarantus BioScience
Holdings, Inc. - 
Dec. 12, 2014
 Developing an Accurate Test for Multiple Sclerosis - Mar. 5, 2014


Contact Information

Amarantus BioScience Holdings, Inc.
655 Montgomery Street
Suite 900
San Francisco, CA 94111


c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva

Phone: (415) 688-4484
Fax: (408) 852-4427

Gerald's email address

IR Calendar 



Jenene Thomas Communications
Jenene Thomas
T: 908-938-1475



VStock Transfer, LLC
Allison Niccols
77 Spruce Street
Suite 201
Cedarhurst, N 11516
T: 212-828-8436
F: 646-536-3179


Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline.

  Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information
         “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise.

   Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.


                                           Three Conferences       

                 Sichenzia Ross Friedman Ference LLP, 61 Broadway, 32nd Floor, New York, NY 10006,
                        on Monday, December 7, 2015, at 10:30 a.m Eastern Time   -  
Proxy Statement 


   People's Bank of China (PBOC) and Anhui Province government to participate in the Anhui SME Cross-border Investment and
     Trade Cooperation Conference (CITCC) being held on 
December 9-10, 2015, in Hefei City Anhui Province, China.  

                       JP Morgan Healthcare on January 11, 2016


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
AMBS News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 11/27/2015 04:16:33 PM
AMBS News: Quarterly Report (10-q) 11/23/2015 05:25:28 PM
AMBS News: Current Report Filing (8-k) 11/19/2015 04:13:19 PM
AMBS News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 11/13/2015 04:18:17 PM
AMBS News: Amarantus Selected by People's Bank of China for Anhui SME Cross-Border Investment and Trade Cooperation Conference 11/13/2015 08:30:00 AM
#119628  Sticky Note Surprise:another dilution event. alexander77 11/14/15 07:23:39 AM
#119333  Sticky Note Partnership with U.S. Army and Orphan Drug Application Rosym 11/05/15 02:38:22 PM
#117775  Sticky Note A leg up on multiple sclerosis (and Alzheimer’s) zoomboom 09/18/15 12:03:13 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#119988   Go $ambs news soon!? :-D Cbdpotential 11/29/15 11:32:30 PM
#119987   yes it really is but obviously tweeting doesn't brharris 11/29/15 10:40:43 PM
#119986   You're correct. I found out at Edgar. I'm jugs 11/29/15 10:27:50 PM
#119985   AMBS filed an 8K a long time ago zoomboom 11/29/15 09:29:42 PM
#119984   It is not acceptable as a form of jugs 11/29/15 09:24:58 PM
#119983   $AMBS ESS -Burn Care 3.0: Tissue-Engineered Skin is zoomboom 11/29/15 09:08:25 PM
#119982   The SEC has no issues with CEO's tweeting. brharris 11/29/15 08:30:13 PM
#119981   The Chinese are interested in what AMBS owes, brharris 11/29/15 08:28:23 PM
#119980   Tweeting targets a select audience. The SEC won't jugs 11/29/15 08:28:12 PM
#119979   GC has been tweeting as of late so brharris 11/29/15 08:21:39 PM
#119978   Are the Chinese likely to ignore Gerald's track Titan V 11/29/15 05:15:47 PM
#119977   Why is Gerald hiding himself from us is JPetroInc 11/29/15 01:46:56 PM
#119976   Why do you think Gerald is hiding himself sante1 11/29/15 12:21:33 PM
#119975   Chinese investors are aggressive and they have global GS1 11/29/15 12:10:41 PM
#119974   Don't underestimate the Chinese investor! They do hard sante1 11/29/15 11:59:18 AM
#119973 GS1 11/29/15 11:52:01 AM
#119972   The idea is to get less toxic and GS1 11/29/15 11:15:33 AM
#119971   There won't be much business to go on SidVicious 11/29/15 10:26:25 AM
#119970   How much money did Amarantus Bioscience Holdings Inc’s JPetroInc 11/29/15 10:26:08 AM
#119969   Don't expect to much from this conference. Hopefully sante1 11/29/15 10:22:44 AM
#119967   Are u seriously down 270k??? alricking 11/29/15 02:25:04 AM
#119966   JP, Please keep us posted on that CA. BBalls-N-CowTown 11/28/15 09:19:13 PM
#119963   $12.00 pps break even from before the catastrophic JPetroInc 11/28/15 07:55:38 PM
#119962   He doesn't deserve one cent based on his SidVicious 11/28/15 07:50:40 PM
#119960   How much money did Gerald Commissiong make total JPetroInc 11/28/15 07:30:27 PM
#119959   Gerald has no control over shareholders buying and Rosym 11/28/15 07:18:51 PM
#119958   Gerald's pay is still too much for a SidVicious 11/28/15 07:17:36 PM
#119956   please don't asssume you know me, my approach JPetroInc 11/28/15 06:47:19 PM
#119955   Buddy, I really feel your pain..GC may or christjamin 11/28/15 06:20:33 PM
#119954   or they sell some of the broken liabilities JPetroInc 11/28/15 06:09:52 PM
#119953   "buys look like sells" JPetroInc 11/28/15 06:03:18 PM
#119952   They should have gone after Asian investors but GS1 11/28/15 04:39:08 PM
#119950   The USDOD, AFIRM or CRADA will not provide JPetroInc 11/28/15 03:53:57 PM
#119949   The upcoming Chinese investor conference will be interesting GS1 11/28/15 01:33:39 PM
#119948   I forgot der_deutschetrader 11/28/15 01:00:31 PM
#119947   no partnering der_deutschetrader 11/28/15 12:58:44 PM
#119944   That's what holding things up but there is GS1 11/28/15 12:46:57 PM
#119943   Lonza is responsible for bringing product to market GS1 11/28/15 12:29:29 PM
#119942   GC also told us the market for Lympro leslunier 11/28/15 12:21:48 PM
#119941   Yes it does but in whose hands? Current Ragnaroc 11/28/15 12:05:59 PM
#119940   ESS has huge potential GS1 11/28/15 11:34:14 AM
#119937   Prospectus filed pursuant to Rule 424(b)(5) zynomat 11/27/15 04:29:48 PM
#119931   sorry I wasted my time asking.... JPetroInc 11/27/15 01:43:29 PM
#119930   Turn head sideways to the left :-D Cbdpotential 11/27/15 01:40:20 PM
#119929   not a mind reader - whats you 8-0 JPetroInc 11/27/15 01:39:40 PM
#119927  Restored check their floorless converts before you get too cheery.... JPetroInc 11/27/15 01:37:52 PM
#119926   The sentiment here is perfect :-D Can't wait till Cbdpotential 11/27/15 12:50:54 PM
#119924   at $320,000/yr. salary, cheap warrants, free travel, full JPetroInc 11/27/15 10:38:10 AM
#119923   Reff> 119921 GC with his rapp music, 0-100 Shadowfaxin 11/27/15 10:31:17 AM
#119922  Restored Josh Sason took AMBS seriously too... JPetroInc 11/27/15 10:20:20 AM